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Influenza is a severe respiratory tract infection caused by influenza viruses. The increasing number of highly 
pathogenic avian influenza (HPAI) virus outbreaks, generally H5 and H7 subtypes, underlines the threat of a 
possible pandemic. The recent HPAI H5 outbreak in domestic poultry and wild birds in US from December 2014 
to June 2015, affecting almost 50 million birds and resulting in $3.3 billion economic losses due to the death and 
culling of poultry, has demonstrated the lack of capabilities to control the rapid spread of avian influenza. Poultry 
vaccination has been shown to not only reduce the virus spread in animals but also reduce the virus 
transmission to humans, preventing potential pandemic development. However, existing vaccine technologies 
could not respond to a new virus outbreak rapidly and at a cost and scale that is commercially viable for mass 
poultry vaccination. Here, we developed modular capsomeres, building blocks of virus-like particle, as a low-
cost poultry influenza vaccine. Modified murine polyomavirus (MuPyV) VP1 capsomere was used to present 
structural-based designed influenza Hemagglutinin (HA1) antigen. Six constructs of modular capsomeres 
presenting three truncated versions of HA1 and two constructs of modular capsomeres presenting non-modified 
HA1 have been generated. Modular capsomeres presenting HA1 were successfully produced in stable forms 
using Escherichia coli, without the need for protein refolding process. This adjuvanted modular capsomere 
(CapHA1) induced strong antibody responses (almost 105 endpoint titre) when administered into chickens, 
similar to titres obtained in the group administered with insect cell-based HA1 proteins. Based on our process 
simulation, 320 million doses of modular capsomere vaccines can be produced in 2.3 days, at a cost of less 
than 1 cent per dose. The result presented here indicated that this platform for bacterially-produced modular 
capsomere could potentially translate into a rapid-response and low-cost vaccine manufacturing technology 
suitable for poultry vaccination. 
 
 
 
